Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals

Completed · Phase 2 · Has a placebo group

Conditions studied: Ischemic Stroke, Malignant Edema

In brief

This is a randomized, multi-center, prospective, double blind study. The primary objective is to assess the efficacy and safety of glyburide (RP-1127) compared to placebo in participants with a severe anterior circulation ischemic stroke who are likely to develop malignant edema.This objective will be addressed by comparing the proportion of glyburide treated particpants and placebo treated participants with a Day 90 modified Rankin Scale (mRS) ≤ 4 without decompressive craniectomy (DC). The secondary objective is to assess the efficacy of RP-1127 compared to placebo in participants with a severe anterior circulation ischemic stroke who were likely to develop malignant edema.

Key facts

Study ID
NCT01794182
Run by
Remedy Pharmaceuticals, Inc.
People needed
86
Starts
2013-06-13
Expected to finish
2016-04-04
Last updated by the study team
2024-11-12

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.